查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813897

阿兹海默症诊断血液生物标记市场规模、份额和趋势分析报告：按类型、技术、最终用途、地区和细分市场预测，2025 年至 2033 年

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Type, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

阿兹海默症血液生物标记市场摘要

2024 年全球阿兹海默症诊断血液生物标记市场规模预计为 1.3969 亿美元，预计到 2033 年将达到 4.2931 亿美元，2025 年至 2033 年的复合年增长率为 15.07%。

一个关键的催化剂是美国FDA 于 2025 年 5 月 16 日批准FUJIREBIO的 Lumipulse G pTau217/B-淀粉样蛋白 1-42 血浆比例的上市销售。

这些措施预计将减少实施过程中的摩擦（监管清晰度、分布），加速支付方的采用和临床医生的诊疗，并加强血液检测相对于影像学和脑脊髓液检测的增长轨迹。根据AAIC 2025上提出并由阿兹海默症协会发布的指南，敏感性≥90%、特异性≥75-90%的血液生物标记(BBM)检测可以对合适的患者进行淀粉样蛋白PET或脑脊髓液检测的分类，如果检测结果良好，则有可能取代这些检测。现实世界的产品数据正在趋于一致。 Quest的2025 AD-Detect™在AAN上发表的一项分析中报告了其对老年痴呆症症病理的敏感性和特异性≥90%，而临床摘要则强调了FDA核准的Lumipulse检测的阳性一致率约为92%，阴性一致率约为97%。随着临床医生对纳入/排除的准确性越来越有信心，诊断将从专科记忆诊所转移到更广泛的环境，检测量将扩大，BBM 将成为诊断的标准化第一步。

该技术的成熟和临床检验继续获得动力：针对磷酸化Tau （特别是 p- 医疗设备 ）的血液测试已被授予突破性设备称号，并且现在已获得 FDA 的完全批准，反映了其较高的临床有效性和效用。

产学研联盟（例如威斯康辛大学麦迪逊分校、约翰霍普金斯大学、隆德大学）提供了关键数据，支持已批准的体外诊断。已发表的评论得出结论，血液生物标记检测 (BBMT) 的价值在于，它能够降低侵入性，并实现关键的早期分诊，而疾病修正治疗在前驱期/轻度阶段最为有效。市场驱动力的例子包括参考实验室的推出和医院采用记忆临床路径，其中 p-tau217/AB 比值阳性可加快 PET 的安排，而阴性结果则可避免昂贵的扫描。随着平台规模的扩大，扩展的检测菜单（神经丝轻链、GFAP、AB42/40）、反射演算法和捆绑检测组合有望提高灵敏度/特异性，支持纵向监测，并扩大一次性诊断之外的经常性检测收益。

目录

第 1 章阿兹海默症诊断血液生物标记市场：调查方法和范围

第二章阿兹海默症诊断血液生物标记市场：执行摘要

  • 市场概述
  • 类型和技术简介
  • 最终用途简介
  • 竞争格局简介

第三章阿兹海默症诊断血液生物标记市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素分析
    • 监管部门核准和临床检验
    • 对早期非侵入性诊断的需求不断增加
    • 与疾病修正治疗（DMTS）的整合
  • 市场限制因素分析
    • 报销和覆盖范围挑战
    • 标准化和检验的障碍
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章阿兹海默症诊断市场血液生物标记：类型估计和趋势分析

  • 阿兹海默症诊断血液生物标记市场：类型变异分析
  • 淀粉样蛋白相关标记物
  • Tau相关标誌物
  • 神经退化
  • 其他的

第五章阿兹海默症诊断市场血液生物标记：技术评估和趋势分析

  • 阿兹海默症诊断血液生物标记市场：技术变革分析
  • 免疫检测
  • 基于质谱的检测
  • 下一代平台
  • 其他的

第六章阿兹海默症诊断血液生物标记市场：最终用途估计和趋势分析

  • 阿兹海默症诊断血液生物标记市场：最终用途变异分析
  • 临床和医院实验室
  • 製药和生物技术
    • 2021-2033年收益估算与预测
  • 学术研究机构
  • 其他的

第七章阿兹海默症诊断血液生物标记市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争态势

  • 公司分类
  • 战略地图
    • 新产品发布
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 2024年主要企业市占率分析
  • 公司热图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Quanterix
    • Fujirebio
    • C2N Diagnostics
    • Labcorp
    • Quest Diagnostics Incorporated
    • Siemens Healthineers
    • Lilly USA, LLC
    • Abbott
    • ALZpath
Product Code: GVR-4-68040-720-2

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Summary

The global blood-based biomarker for Alzheimer's disease diagnostics market size was estimated at USD 139.69 million in 2024 and is expected to reach USD 429.31 million by 2033, growing at a CAGR of 15.07% from 2025 to 2033. A pivotal catalyst was the U.S. FDA's May 16, 2025, marketing clearance of Fujirebio's Lumipulse G pTau217/B-amyloid 1-42 plasma ratio-the first Alzheimer's blood test cleared to aid diagnosis-quickly followed by Labcorp's nationwide launch on Aug 18, 2025.

These steps lower adoption friction (regulatory clarity, distribution) and are expected to accelerate payer uptake and clinician ordering, intensifying the growth curve for blood tests relative to imaging and CSF. Guidance presented at AAIC 2025 and published by the Alzheimer's Association states that blood-based biomarker (BBM) tests with >=90% sensitivity and >=75-90% specificity can triage-and at higher performance, substitute for-amyloid PET or CSF testing in appropriate patients. p-tau217-containing panels consistently outperform earlier generations (AB42/40 or p-tau181 alone) for detecting amyloid and tau pathology. Real-world product data are converging: Quest's 2025 AD-Detect(TM) reported >90% sensitivity and specificity for Alzheimer's pathology in AAN-presented analyses, while clinical summaries highlight ~92% positive and ~97% negative agreement for the FDA-cleared Lumipulse test. As clinicians gain confidence in rule-in/rule-out accuracy, ordering shifts from specialty memory clinics to broader frontline settings, expanding test volumes and normalizing BBMs as the first diagnostic step.

Technology maturation and clinical validation add momentum. Blood assays targeting phosphorylated tau (especially p-tau217) have received Breakthrough Device designations and now full FDA clearance, reflecting strong clinical validity and utility.

Academic-industry consortia (e.g., UW-Madison, Johns Hopkins, Lund) supplied pivotal data underpinning the cleared IVD. Published reviews conclude that blood-based biomarker tests (BBMTs) bring value by reducing invasiveness and enabling earlier triage-crucial when disease-modifying therapies are most effective in prodromal/mild stages. Market traction examples include reference-lab launches and hospital adoption for memory-clinic pathways, where a positive p-tau217/AB ratio can expedite PET scheduling while a negative result can avoid costly scans. As platforms scale, expect menu expansion (neurofilament light, GFAP, AB42/40), reflex algorithms, and bundled panels, improving sensitivity/specificity and supporting longitudinal monitoring-opening recurring-test revenue beyond one-time diagnosis.

Global Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood-based biomarker for Alzheimer's disease diagnostics market report based on type, technology, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Amyloid-related markers
  • Tau-related markers
  • Neurodegeneration
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassays
  • Mass spectrometry-based assays
  • Next-generation platforms
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical laboratories & hospital labs
  • Pharma & biotech
  • Academic & research institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Regulatory approvals and clinical validation
    • 3.4.2. Rising demand for early and non-invasive diagnosis
    • 3.4.3. Integration with disease-modifying therapies (DMTS)
  • 3.5. Market Restraint Analysis
    • 3.5.1. Reimbursement and coverage challenges
    • 3.5.2. Standardization and validation barriers
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Movement Analysis
  • 4.2. Amyloid-related markers
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Tau-related markers
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Neurodegeneration
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Estimates & Trend Analysis

  • 5.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Mass spectrometry-based assays
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Next-generation platforms
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Movement Analysis
  • 6.2. Clinical laboratories & hospital labs
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Pharma & biotech
    • 6.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Academic & research institutes
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Production Launch
    • 8.2.2. Patnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Quanterix
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fujirebio
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. C2N Diagnostics
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Labcorp
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Quest Diagnostics Incorporated
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Siemens Healthineers
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Lilly USA, LLC
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Abbott
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. ALZpath
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 5 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 9 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 25 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 31 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 56 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 59 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 32021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Blood-based biomarker for Alzheimer's disease diagnostics market- Key market driver analysis
  • Fig. 7 Global Blood-based biomarker for Alzheimer's disease diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Blood-based biomarker for Alzheimer's disease diagnostics market - Porter's analysis
  • Fig. 10 Global Blood-based biomarker for Alzheimer's disease diagnostics market - PESTEL analysis
  • Fig. 11 Global Blood-based biomarker for Alzheimer's disease diagnostics market Type outlook key takeaways
  • Fig. 12 Global Blood-based biomarker for Alzheimer's disease diagnostics market: Type movement analysis
  • Fig. 13 Amyloid-related markers market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Tau-related markers market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Neurodegeneration market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Global Blood-based biomarker for Alzheimer's disease diagnostics market technology outlook key takeaways
  • Fig. 18 Global Blood-based biomarker for Alzheimer's disease diagnostics market: technology movement analysis
  • Fig. 19 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Mass spectrometry-based assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Next-generation platforms market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Global Blood-based biomarker for Alzheimer's disease diagnostics market end use outlook key takeaways
  • Fig. 24 Global Blood-based biomarker for Alzheimer's disease diagnostics market: end use movement analysis
  • Fig. 25 Clinical laboratories & hospital labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Pharma & biotech market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Academic & research institutes market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics market: Regional movement analysis
  • Fig. 31 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 36 UK Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 38 France Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 39 Spain Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 41 Denmark Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 44 Asia Pacific Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 45 Japan Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 46 China Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 47 India Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 48 South Korea Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 49 Australia Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 50 Thailand Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 51 Latin America Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 52 Brazil Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 53 Argentina Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 54 MEA Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 55 South Africa Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 56 Saudi Arabia Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 57 UAE Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 58 Kuwait Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 59 Strategy framework